Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
SAB Biotherapeutics, Inc. - Common Stock
(NQ:
SABS
)
2.550
-0.040 (-1.54%)
Delayed Quote
Updated: 9:56 AM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SAB Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 18, 2024
Via
Benzinga
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
September 13, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
September 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
↗
August 09, 2024
SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
August 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
August 05, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
SAB BIO Appoints Lucy To as Chief Financial Officer
July 31, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO
June 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 18, 2024
Via
Benzinga
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
June 18, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 23, 2024
Via
Benzinga
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
↗
May 21, 2024
SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
May 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
March 25, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
February 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday
↗
January 03, 2024
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
